Gene-Driven Adjuvant Therapy for NSCLC Leads to Big Improvement in DFS

By News Health
2 days Ago

(MedPage Today) — CHICAGO — Biomarker-driven adjuvant therapy for intermediate/high-risk non-small cell lung cancer (NSCLC) led to significantly longer disease-free survival (DFS) as compared with observation, a randomized trial showed.
DFS…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115810

Author :

Publish date : 2025-05-31 12:00:00

Copyright for syndicated content belongs to the linked Source.

Categories: Health News

Related Content

Tumor Treating Fields Boost Pancreatic Cancer Survival

Alternative Endpoints in Phase III Trials Don't Always Mean Boosts to OS, QOL

This Diet Pattern Is Linked With Worse Survival in Colon Cancer

Add-On Nivolumab Extends DFS in Locally Advanced Head and Neck Cancer

In Pancreatic Cancer, Does New PAXG Beat Out mFOLFIRINOX?

'This Is Not Just a Pandemic Story': What We Heard This Week